Benzinga · Nov 13, 2026
Morgan Stanley Maintains Equal-Weight on Genmab, Lowers Price Target to $56
Morgan Stanley analyst Judah Frommer maintains Genmab (NASDAQ:GMAB) with a Equal-Weight and lowers the price target from $57 to $56.
NASDAQ · GMAB
Healthcare · Biotechnology
$50.97
Up+$0.38 (+0.75%)
Updated Nov 20, 2026, 1:51 AM
SID Score
8.1/10
Composite research score
Smart Money
60/100
Neutral
Price performance · GMAB
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 18, 2026
GMAB closed at $50.97 after 20 trading sessions, up 27.42% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 18, 2026 | $51.60 | $52.26 | $50.89 | $50.97 | 2.96M |
| Nov 17, 2026 | $50.90 | $52.08 | $50.86 | $51.96 | 3.32M |
| Nov 16, 2026 | $52.615 | $52.82 | $51.51 | $51.57 | 2.43M |
| Nov 13, 2026 | $51.22 | $51.615 | $50.68 | $51.37 | 3.73M |
| Nov 12, 2026 | $52.20 | $53.03 | $51.535 | $51.74 | 5.63M |
| Nov 11, 2026 | $52.89 | $54.09 | $52.32 | $53.87 | 3.92M |
| Nov 10, 2026 | $54.87 | $55.23 | $53.15 | $54.07 | 3.09M |
| Nov 9, 2026 | $54.36 | $55.91 | $53.315 | $55.80 | 5.14M |
| Nov 6, 2026 | $52.36 | $54.15 | $51.2243 | $53.63 | 7.83M |
| Nov 5, 2026 | $55.07 | $55.27 | $52.6201 | $52.74 | 4.4M |
| Nov 4, 2026 | $56.01 | $56.20 | $53.76 | $55.12 | 4.3M |
| Nov 3, 2026 | $55.46 | $56.50 | $55.10 | $55.52 | 3.06M |
| Nov 2, 2026 | $56.21 | $56.84 | $54.645 | $54.92 | 4.42M |
| Oct 30, 2026 | $57.40 | $59.0228 | $56.53 | $57.06 | 8.65M |
| Oct 29, 2026 | $56.56 | $58.19 | $55.68 | $56.49 | 6.25M |
| Oct 28, 2026 | $44.63 | $59.97 | $44.35 | $57.29 | 29.28M |
| Oct 27, 2026 | $44.41 | $44.99 | $43.98 | $44.67 | 4.93M |
| Oct 26, 2026 | $44.79 | $45.445 | $44.08 | $44.685 | 7.47M |
| Oct 23, 2026 | $39.84 | $44.34 | $39.635 | $43.79 | 13M |
| Oct 22, 2026 | $39.675 | $40.165 | $39.50 | $40.00 | 4.69M |
The latest Smart Investors Daily articles mentioning GMAB.
Company
Market Activity
Research & News
GMAB research
Company profile and research snapshot.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Sep 23, 2026 | JYSKE BANK | Buy | — |
| Sep 14, 2026 | H.C. WAINWRIGHT & CO., LLC | Buy | — |
| Aug 31, 2026 | BNP PARIBAS | Outperform | — |
| Aug 7, 2026 | DNB CARNEGIE | Buy | — |
No generated briefing is available yet.
Benzinga · Nov 13, 2026
Morgan Stanley analyst Judah Frommer maintains Genmab (NASDAQ:GMAB) with a Equal-Weight and lowers the price target from $57 to $56.
Yahoo · Nov 13, 2026
Genmab has delivered a sharp rerating over the past year, and the question now is whether the current share price is properly supported by the cash flows investors can reasonably expect from the business. With the Discounted Cash Flow (DCF) intrinsic value estimate pointing squarely at those cash flows, the recent surge puts that framework under the spotlight. Over the past 12 months the stock has gained 79.7%, which puts a lot of weight on the idea that future cash generation will grow into...
Yahoo · Nov 12, 2026
Company Announcement COPENHAGEN, Denmark; November 12, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in
Yahoo · Nov 10, 2026
Company Announcement COPENHAGEN, Denmark; November 10, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 164,828 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,961 shares at DKK 1,362.5,17,676 shares at DKK 1,615,949 shares at DKK 1,948,25,635 shares at DKK 2,070,6,1
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning GMAB.